Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
RDVY vs XBI: how they differ
RDVY and XBI hold 1% of their weight in the same names, and XBI returned more over the year.
First Trust Rising Dividend Achievers ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, RDVY and XBI hold 1% of their money in the same securities at the same weight.
| Holding | RDVY | XBI |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 1.10% | 1.27% |
| Only in RDVY | Only in XBI |
|---|---|
| Lam Research Corporation 3.09% | MODERNA INC 2.87% |
| Applied Materials, Inc. 2.99% | TWIST BIOSCIENCE CORP 1.81% |
| KLA Corporation 2.47% | HALOZYME THERAPEUTICS INC 1.47% |
| The Bank of New York Mellon Corporation 2.46% | NATERA INC 1.46% |
| The Travelers Companies, Inc. 2.26% | KYMERA THERAPEUTICS INC 1.45% |
| GE Vernova Inc. 2.24% | TRAVERE THERAPEUTICS INC 1.40% |
| Bank of America Corporation 2.18% | ROIVANT SCIENCES LTD 1.39% |
| Ross Stores, Inc. 2.16% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| RDVY First Trust Rising Dividend Achievers ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | First Trust | State Street |
| What it is | First Rising Dividend Achievers | SPDR S&P Biotech |
| Total return, 1 year | +22.0% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +4.5 pts | +46.5 pts |
| Expense ratio | 0.47% | 0.35% |
| Already in the S&P 500 | 94.4% | 8.5% |
| Holdings | 72 | 154 |
RDVY in plain words
RDVY is an index equity fund tracking the First Rising Dividend Achievers. Over the year to Sep 11, 2026 it returned +22.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.47% a year. By its holdings filed for Sep 10, 2026, 94% of the fund by weight is stocks the S&P 500 also holds, across 72 positions, with the top ten at 24.1%. It sat 3.9% below its high of Aug 13, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, RDVY or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, RDVY returned +22.0% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, RDVY or XBI?
- RDVY charges 0.47% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do RDVY and XBI overlap with the S&P 500?
- By their latest filed holdings, 94% of RDVY and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, RDVY against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/rdvy-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources